Clinical Characteristics and Outcomes of Critically ill Mechanically Ventilated COVID-19 Patients Receiving interleukin-6 Receptor Antagonists and Corticosteroid Therapy: A Multicenter International Observational Study
Abstract Objectives The interest in interleukin-6 receptor antagonists (IL-6RA) and steroids have increased recently due to their potential role as immunomodulatory effect in critically ill coronavirus disease (COVID-19). The magnitude of this therapy in subgroups of patients with invasive mechanical ventilation (MV) remains to be fully clarified. We compared the clinical characteristics and outcomes of patients requiring iMV, and receiving IL-6RA and steroids with different steroids regimens.Design International, multicenter, observational study derived from Viral Infection and Respiratory Illness University Study registry and conducted through Discovery Network, Society of Critical Care Medicine. Marginal structural modeling was used to adjust time-dependent confounders; observations were weighted using inverse probability of treatment weight. A sensitivity analysis was conducted for target trial design.Setting 168 hospitals, 16 countries.Patients Covid-19 ICU patients (≥18 years) requiring MV between March 01,2020, and January 10,2021.Intervention None.Measurements and Main Results Of 860 patients met eligibility criteria, 589 received steroids, 170 IL-6RA, and 101 combinations; groups were balanced after adjustment. Median daily steroid dose was 7.5 mg dexamethasone or equivalent (IQR:6-14 mg); 80.8% and 19.2% received low-dose and high-dose steroids, respectively. The median C-reactive protein level was >75 mg/L in majority of our cohort. The use of IL-6R antagonists alone or in combination was not associated with a significant difference in ventilator-free days (VFD) compared to steroids alone with different steroids regimens (adjusted incidence rate ratio [95% CI]): IL-6R antagonists (1.12 [0.88,1.4]), combination (0.83 [0.6,1.14]). Patients treated with low or high-dose steroids had non-significant differences in VFD compared to IL-6RA (ß=0.62, 95% CI −1.54,2.78 for low-dose steroid; ß=-1.19, 95% CI −3.85,1.47 for high-dose steroid). There was no difference in 28-day mortality and hospital mortality with IL-6RA alone or in combination compared to steroids alone (28-day mortality adjusted odds ratio [95% CI]): IL-6RA (0.68[0.44,1.07]), combination (1.07[0.67,1.70]). Sensitivity analysis findings were consistent with primary analysis. Liver dysfunction was higher in IL-6RA (p=0.04) while rate of bacteremia did not differ among groups.Conclusions In adult ICU COVID-19 patients on iMV, we found no difference in outcomes between those who received IL-6RA, steroids, or combination therapy and those who received IL-6RA or low-or high-dose steroids. Further randomized trials are needed to enhance our understanding for IL-6RA safety with different steroids regimen and the magnitude of benefit in those subgroups of patients..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
bioRxiv.org - (2023) vom: 02. Nov. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Amer, Marwa [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.1101/2021.04.12.21255323 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI020349602 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI020349602 | ||
| 003 | DE-627 | ||
| 005 | 20231102090815.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210414s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2021.04.12.21255323 |2 doi | |
| 035 | |a (DE-627)XBI020349602 | ||
| 035 | |a (biorXiv)10.1101/2021.04.12.21255323 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Amer, Marwa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical Characteristics and Outcomes of Critically ill Mechanically Ventilated COVID-19 Patients Receiving interleukin-6 Receptor Antagonists and Corticosteroid Therapy: A Multicenter International Observational Study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Objectives The interest in interleukin-6 receptor antagonists (IL-6RA) and steroids have increased recently due to their potential role as immunomodulatory effect in critically ill coronavirus disease (COVID-19). The magnitude of this therapy in subgroups of patients with invasive mechanical ventilation (MV) remains to be fully clarified. We compared the clinical characteristics and outcomes of patients requiring iMV, and receiving IL-6RA and steroids with different steroids regimens.Design International, multicenter, observational study derived from Viral Infection and Respiratory Illness University Study registry and conducted through Discovery Network, Society of Critical Care Medicine. Marginal structural modeling was used to adjust time-dependent confounders; observations were weighted using inverse probability of treatment weight. A sensitivity analysis was conducted for target trial design.Setting 168 hospitals, 16 countries.Patients Covid-19 ICU patients (≥18 years) requiring MV between March 01,2020, and January 10,2021.Intervention None.Measurements and Main Results Of 860 patients met eligibility criteria, 589 received steroids, 170 IL-6RA, and 101 combinations; groups were balanced after adjustment. Median daily steroid dose was 7.5 mg dexamethasone or equivalent (IQR:6-14 mg); 80.8% and 19.2% received low-dose and high-dose steroids, respectively. The median C-reactive protein level was >75 mg/L in majority of our cohort. The use of IL-6R antagonists alone or in combination was not associated with a significant difference in ventilator-free days (VFD) compared to steroids alone with different steroids regimens (adjusted incidence rate ratio [95% CI]): IL-6R antagonists (1.12 [0.88,1.4]), combination (0.83 [0.6,1.14]). Patients treated with low or high-dose steroids had non-significant differences in VFD compared to IL-6RA (ß=0.62, 95% CI −1.54,2.78 for low-dose steroid; ß=-1.19, 95% CI −3.85,1.47 for high-dose steroid). There was no difference in 28-day mortality and hospital mortality with IL-6RA alone or in combination compared to steroids alone (28-day mortality adjusted odds ratio [95% CI]): IL-6RA (0.68[0.44,1.07]), combination (1.07[0.67,1.70]). Sensitivity analysis findings were consistent with primary analysis. Liver dysfunction was higher in IL-6RA (p=0.04) while rate of bacteremia did not differ among groups.Conclusions In adult ICU COVID-19 patients on iMV, we found no difference in outcomes between those who received IL-6RA, steroids, or combination therapy and those who received IL-6RA or low-or high-dose steroids. Further randomized trials are needed to enhance our understanding for IL-6RA safety with different steroids regimen and the magnitude of benefit in those subgroups of patients. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Bawazeer, Mohammed |4 aut | |
| 700 | 1 | |a Maghrabi, Khalid |4 aut | |
| 700 | 1 | |a Kamel, Ahmed M. |4 aut | |
| 700 | 1 | |a Butt, Abid |4 aut | |
| 700 | 1 | |a Dahhan, Talal |4 aut | |
| 700 | 1 | |a Kseibi, Eiad |4 aut | |
| 700 | 1 | |a Khurshid, Syed Moazzum |4 aut | |
| 700 | 1 | |a Abujazar, Mohammed |4 aut | |
| 700 | 1 | |a Alghunaim, Razan |4 aut | |
| 700 | 1 | |a Rabee, Muath |4 aut | |
| 700 | 1 | |a Abualkhair, Maal |4 aut | |
| 700 | 1 | |a Al-Janoubi, Ali |4 aut | |
| 700 | 1 | |a AlFirm, Abeer Turki |4 aut | |
| 700 | 1 | |a Gajic, Ognjen |4 aut | |
| 700 | 1 | |a Walkey, Allan J. |4 aut | |
| 700 | 1 | |a Mosier, Jarrod M |4 aut | |
| 700 | 1 | |a Zabolotskikh, Igor Borisovich |4 aut | |
| 700 | 1 | |a Gavidia, Oscar Y |4 aut | |
| 700 | 1 | |a Teruel, Santiago Y. |4 aut | |
| 700 | 1 | |a Bernstein, Michael A. |4 aut | |
| 700 | 1 | |a Boman, Karen |4 aut | |
| 700 | 1 | |a Kumar, Vishakha K. |4 aut | |
| 700 | 1 | |a Bansal, Vikas |4 aut | |
| 700 | 1 | |a Kashyap, Rahul |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2023) vom: 02. Nov. |
| 773 | 1 | 8 | |g year:2023 |g day:02 |g month:11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2021.04.12.21255323 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 02 |c 11 | ||